Khosla Ventures

Viome, Inc. is a biotechnology company based in Bellevue, Washington, founded in 2016 by Naveen Jain. The company specializes in wellness monitoring kits that offer comprehensive health insights by analyzing various biological samples, including blood, urine, saliva, and stool. By examining the RNA from stool samples, Viome determines the composition of microbial communities in the digestive system, identifying different species and strains of bacteria, viruses, fungi, and other microorganisms. This analysis is integrated into a smartphone application that provides personalized recommendations for diet and lifestyle adjustments, aiding users in tracking their microbiome health, mitochondrial health, cellular health, and biological age. Viome's products are available through distributors and online, positioning the company as a leader in personalized health solutions.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By leveraging self-supervised learning and integrating human multimodal data, the company aims to enhance the effectiveness and personalization of cancer therapies, thereby improving patient outcomes in oncology.

Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.

YonedaLabs is a developer of AI-based software designed to assist chemists in optimizing various reaction parameters, including temperature, concentration, and catalysts. Their platform aims to enhance the efficiency of chemical laboratories by streamlining the process involved in drug and material production. By leveraging artificial intelligence, YonedaLabs enables businesses to accelerate their research and development efforts, ultimately improving outcomes in the field of chemistry.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.

Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs.

Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company is creating a profiling and engineering technology platform that leverages advanced artificial intelligence to deliver an in-depth understanding of the epigenome in both health and disease. This innovative approach allows healthcare providers to explore new avenues for therapy discovery and facilitates the reprogramming of cells to restore their healthy state. By integrating AI-driven insights, Moonwalk Biosciences aims to transform the landscape of therapeutic development and improve patient outcomes.

Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies. Its platform cultures the most realistic human tissues ever lab-grown to answer deep questions about human health.

CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.

Rejuvenation Technologies Inc. is a biotechnology company based in Mountain View, California, focused on developing nucleoside-modified telomerase reverse transcriptase messenger RNA to extend telomeres and promote human health. The company's innovative approach involves delivering a telomere extender that encodes telomerase reverse transcriptase, which transiently boosts telomerase activity in cells. This technology aims to enhance the proliferative capacity of cells, potentially addressing age-related diseases and conditions in various medical fields, including hepatic, pulmonary, and immunology. Additionally, Rejuvenation Technologies offers a range of cell therapies that encompass tissue engineering, cell transplants, skin grafts, immunotherapy, and regenerative medicine. Established in 2016, the company is dedicated to advancing solutions in regenerative health.

Viome, Inc. is a biotechnology company based in Bellevue, Washington, founded in 2016 by Naveen Jain. The company specializes in wellness monitoring kits that offer comprehensive health insights by analyzing various biological samples, including blood, urine, saliva, and stool. By examining the RNA from stool samples, Viome determines the composition of microbial communities in the digestive system, identifying different species and strains of bacteria, viruses, fungi, and other microorganisms. This analysis is integrated into a smartphone application that provides personalized recommendations for diet and lifestyle adjustments, aiding users in tracking their microbiome health, mitochondrial health, cellular health, and biological age. Viome's products are available through distributors and online, positioning the company as a leader in personalized health solutions.

SiPhox Health develops advanced diagnostic solutions for both home use and laboratory settings. The company offers an at-home test kit that evaluates 17 blood biomarkers, focusing on areas such as inflammation, hormonal health, metabolic fitness, and cardiovascular health. Their biosensing platform features a handheld device designed to work with disposable cartridges, integrating biochemistry and photonic chip technology. This innovative approach combines integrated photonics, electronics, and microfluidics to deliver sensitive readings of immunoassays and nucleic acids, facilitating point-of-need testing and enhancing the accessibility of diagnostic tools for users.

SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. The company provides an injectable biodegradable hydrogel that allows for the prolonged, localized release of most cancer immunotherapy on the website of surgical tumor resection by focusing the dose at the right place and right time.

SiPhox Health develops advanced diagnostic solutions for both home use and laboratory settings. The company offers an at-home test kit that evaluates 17 blood biomarkers, focusing on areas such as inflammation, hormonal health, metabolic fitness, and cardiovascular health. Their biosensing platform features a handheld device designed to work with disposable cartridges, integrating biochemistry and photonic chip technology. This innovative approach combines integrated photonics, electronics, and microfluidics to deliver sensitive readings of immunoassays and nucleic acids, facilitating point-of-need testing and enhancing the accessibility of diagnostic tools for users.

Ceibo is an industrial biotechnology company dedicated to providing innovative solutions for the mining industry, particularly in the production of critical minerals essential for the clean energy transition. The company has developed proprietary technology for leaching copper sulfide, which enhances recovery from both primary and secondary sulfide ores rich in chalcopyrite. In addition to its leaching technology, Ceibo has implemented technologies aimed at dust suppression in mining operations. Currently, Ceibo operates within several large mining assets owned by prominent mining companies, focusing on optimizing processes, reducing costs, and promoting environmentally sustainable practices with a commitment to zero waste activity.

Tachyon Therapeutics is a biotechnology company focused on developing innovative therapeutics for cancer treatment. The firm specializes in creating selective compounds that target significant drug targets within cancer biology, employing advanced methodologies in molecular cancer biology, epigenetics, and cancer stem cell biology. Currently, Tachyon is conducting Phase 1 clinical trials to evaluate the safety, pharmacokinetics, and anti-tumor effectiveness of its lead compound, TACH101, in patients with advanced cancer. The company's research and development efforts aim to unlock new pathways for treating challenging cancer types, ensuring that its programs are advanced in a timely and scientifically rigorous manner.

IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

Synchron develops an implantable medical device known as a stentrode, which is designed to establish a brain-computer interface. This minimally invasive device is delivered to the brain via a catheter and features electrode arrays that interpret neuronal signals. By modulating neural activity in targeted areas, the stentrode enables patients with motor impairments to regain control over digital devices, prosthetics, and other assistive technologies using their thoughts. Synchron's innovative approach aims to enhance the quality of life for individuals with significant mobility challenges.

Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.

SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. The company provides an injectable biodegradable hydrogel that allows for the prolonged, localized release of most cancer immunotherapy on the website of surgical tumor resection by focusing the dose at the right place and right time.

Viome, Inc. is a biotechnology company based in Bellevue, Washington, founded in 2016 by Naveen Jain. The company specializes in wellness monitoring kits that offer comprehensive health insights by analyzing various biological samples, including blood, urine, saliva, and stool. By examining the RNA from stool samples, Viome determines the composition of microbial communities in the digestive system, identifying different species and strains of bacteria, viruses, fungi, and other microorganisms. This analysis is integrated into a smartphone application that provides personalized recommendations for diet and lifestyle adjustments, aiding users in tracking their microbiome health, mitochondrial health, cellular health, and biological age. Viome's products are available through distributors and online, positioning the company as a leader in personalized health solutions.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Equii is a food technology company established in 2021 and located in San Ramon, California. Founded by Monica Bhatia, the company specializes in discovering and utilizing highly nutritious microbial proteins to enhance the fermentation of grains, resulting in high-protein grain flours. Equii's innovative approach transforms agricultural crops into nutritionally balanced products, catering to various eating occasions and providing consumers with access to healthier food options. Through its breakthrough technology, the company aims to deliver complete nutritional solutions, emphasizing the importance of protein-rich diets.

Carver Biosciences is a biotechnology firm specializing in the development of CRISPR/Cas13-based antiviral therapies. The company focuses on creating gene therapies that target RNA viruses, particularly respiratory viruses, at the RNA level. By utilizing the Cas13 technology, Carver aims to destroy these viruses and inhibit their replication. This approach is intended to complement existing vaccination efforts and viral inhibitors, providing patients with alternative treatment options to halt the progression of infections.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.

CHARM Therapeutics is focused on developing innovative medicines using advanced 3D deep learning and drug discovery technologies. The company's platform aims to address undruggable disease targets, providing healthcare professionals with effective treatment options for challenging medical conditions. By leveraging cutting-edge technology, CHARM Therapeutics seeks to create transformative therapies that have the potential to significantly improve patient outcomes.

Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs.

Anagenex is a seed stage biotechnology company focused on advancing drug discovery through its innovative platform. The company aims to tackle challenging pharmaceutical targets by utilizing a technology that combines machine learning with DNA-encoded libraries. This approach allows for the rapid analysis of compounds and the generation of extensive data sets, facilitating parallel biochemical experiments. By leveraging proprietary artificial intelligence models, Anagenex enables researchers to efficiently develop new small molecule drugs for medically significant applications.

Ultima Genomics is unleashing the power of genomics at scale. Ultima Genomics drives the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The company was founded in 2016 and is based in Newark, California.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

VitroLabs, Inc. is a startup based in San Jose, California, specializing in 3D tissue engineering and biomaterials. Founded in 2016, the company focuses on developing a scalable platform that utilizes advanced stem cell technologies to create authentic, lab-grown leather and other biomaterials. VitroLabs aims to provide a sustainable alternative to traditional animal-derived products, enabling fashion brands and interior designers to manufacture high-quality items without the ethical and environmental concerns associated with animal agriculture. By leveraging the latest advancements in stem cell research, VitroLabs is positioned at the forefront of innovation in the biomaterials industry.

Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.

Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in developing tools for biological automation, focusing on scalable automation solutions for genetic engineering. Volta Labs operates a platform designed for affordable genomic sample preparation, aimed at revolutionizing genomics research. This platform leverages automation and miniaturization technologies to streamline the creation of biological samples. By integrating expertise from engineering, surface chemistry, and molecular biology, Volta Labs enables biotech organizations to automate complex biological workflows, facilitating advancements in genomics and genetic engineering.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.

Anagenex is a seed stage biotechnology company focused on advancing drug discovery through its innovative platform. The company aims to tackle challenging pharmaceutical targets by utilizing a technology that combines machine learning with DNA-encoded libraries. This approach allows for the rapid analysis of compounds and the generation of extensive data sets, facilitating parallel biochemical experiments. By leveraging proprietary artificial intelligence models, Anagenex enables researchers to efficiently develop new small molecule drugs for medically significant applications.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

NextVivo is a biotechnology company focused on advancing drug development through its innovative immune organoid technology platform. This platform generates human cell and antibody candidate therapies by harnessing the body's immune system. NextVivo's organoids are miniature 3D cell cultures designed to replicate the composition, structure, and function of human tissues, allowing for a realistic modeling of the humoral and cellular immune responses outside the body. This technology enables the testing of pre-clinical candidates on ex vivo human tissue models, facilitating the identification of the most effective therapies for clinical development. The company's mission is to accelerate the creation of safer and more effective treatments by utilizing immune-competent, human-derived models.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

Viome, Inc. is a biotechnology company based in Bellevue, Washington, founded in 2016 by Naveen Jain. The company specializes in wellness monitoring kits that offer comprehensive health insights by analyzing various biological samples, including blood, urine, saliva, and stool. By examining the RNA from stool samples, Viome determines the composition of microbial communities in the digestive system, identifying different species and strains of bacteria, viruses, fungi, and other microorganisms. This analysis is integrated into a smartphone application that provides personalized recommendations for diet and lifestyle adjustments, aiding users in tracking their microbiome health, mitochondrial health, cellular health, and biological age. Viome's products are available through distributors and online, positioning the company as a leader in personalized health solutions.

Vertical Oceans specializes in producing sustainable, same-day farm-to-fork shrimp using innovative vertical aquaculture towers located in major urban markets. The company employs a comprehensive system that integrates 83 technologies across bioengineering, hardware engineering, and computational engineering to enhance the seafood production process. Central to their operation is the Intelligent Habitat, or iHAB, which functions as a self-sustaining and self-cleaning modular production unit. This unique system incorporates a balanced aquatic ecosystem featuring fish and seaweed for biofiltration, promoting a more natural environment for shrimp cultivation. Vertical Oceans' approach allows for the delivery of fresh shrimp with strong sustainability credentials, while simultaneously eliminating the use of chemicals, antibiotics, and effluent.

Supplant is a biotechnology platform working in the food sector. It develops natural food ingredients from agricultural resources to allow food manufacturers to decrease sugar, increase fiber, and boost the gut health-promoting qualities of its products.

Pearl Bio is a synthetic biology company focused on advancing the field of biologics and biomaterials. It has developed a platform that incorporates genome engineering, ribosome engineering, and biomanufacturing techniques. This platform allows for the creation of innovative biomaterials and smart biologics, enabling researchers to enhance their understanding of gene function. Pearl Bio's work aims to facilitate the development of products and processes that can be utilized at a commercial scale, ultimately providing new avenues for treating genetic and acquired diseases.

VitroLabs, Inc. is a startup based in San Jose, California, specializing in 3D tissue engineering and biomaterials. Founded in 2016, the company focuses on developing a scalable platform that utilizes advanced stem cell technologies to create authentic, lab-grown leather and other biomaterials. VitroLabs aims to provide a sustainable alternative to traditional animal-derived products, enabling fashion brands and interior designers to manufacture high-quality items without the ethical and environmental concerns associated with animal agriculture. By leveraging the latest advancements in stem cell research, VitroLabs is positioned at the forefront of innovation in the biomaterials industry.

Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.

Karma Biotechnologies, Inc. is a Los Angeles-based startup focused on developing therapies for autoimmune diseases, allergies, and food sensitivities. Founded in 2019, the company offers Xavines, a precision immunotherapy platform designed to address the critical need for antigen-specific therapies that target only the rogue immune cells responsible for these conditions. Unlike traditional treatments that rely on general immune suppression, Karma Biotechnologies aims to create tolerogenic immunotherapies that promote antigen-specific immune tolerance in vivo. By leveraging its expertise in immunology and lipid nanoparticle engineering, the company seeks to provide innovative solutions that enhance the treatment landscape for autoimmune diseases and related disorders.

Known Medicine Inc., founded in 2020 and based in Salt Lake City, Utah, specializes in developing a custom organoid platform designed for tumor sensitivity testing. The company aims to enhance cancer treatment by conducting experiments on tumor responses to drugs in a controlled laboratory setting rather than within the patient’s body. Known Medicine's innovative approach involves breaking down tumor samples into microtumors, which are treated in specialized micro-environments using various methods to identify the most effective treatments. The platform utilizes machine learning-based sensitivity assays and integrates omics data to detect different cell types, including cancerous, stromal, and immune cells. This enables oncologists to analyze multiple microtumors, ultimately helping to determine optimal treatment strategies for individual patients.

Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Synchron develops an implantable medical device known as a stentrode, which is designed to establish a brain-computer interface. This minimally invasive device is delivered to the brain via a catheter and features electrode arrays that interpret neuronal signals. By modulating neural activity in targeted areas, the stentrode enables patients with motor impairments to regain control over digital devices, prosthetics, and other assistive technologies using their thoughts. Synchron's innovative approach aims to enhance the quality of life for individuals with significant mobility challenges.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Overture Life, Inc. is a biotechnology company established in 2017 and headquartered in New York, New York. The company specializes in developing robotic technology and medical devices aimed at automating the in vitro fertilization (IVF) process. Overture Life's innovations include novel embryo testing methodologies and automated cryopreservation services, which help fertility clinics identify viable embryos prior to implantation. By streamlining the IVF process, Overture Life aims to make artificial insemination more accessible, reduce costs, optimize resource use, and improve success rates for practitioners and patients alike.

Apton Biosystems, Inc., founded in 2012 and located in Pleasanton, California, operates within the biotechnology industry, focusing on advanced medical technology. The company has developed an innovative optical system for sequencing and protein detection that utilizes super-resolution techniques. This technology allows for the assessment of molecules situated closer than the wavelength of light, facilitating multi-omic sequencing and single-molecule protein detection. Apton's solutions aim to enhance biomarker discovery, enable early disease detection, and support therapeutic monitoring, thereby contributing to advances in preventive health and precision medicine.

Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Supplant is a biotechnology platform working in the food sector. It develops natural food ingredients from agricultural resources to allow food manufacturers to decrease sugar, increase fiber, and boost the gut health-promoting qualities of its products.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Ukko is a biotechnology company focused on enhancing the lives of individuals with food allergies and gluten-related disorders. Utilizing a sophisticated computational engineering platform, Ukko redesigns food allergens into therapeutics that are safe and effective. The company is developing a detailed, clinically validated map of the molecular structures associated with food allergies, which provides insights into the biological mechanisms of human-food interactions. By leveraging this information, Ukko creates modified proteins that do not provoke an immune response, offering a novel approach to treating protein-based allergies. Through the integration of artificial intelligence, immunology, computational biology, and protein engineering, Ukko aims to produce safe protein alternatives that physicians can confidently prescribe to patients.

Earli is a company focused on developing innovative cancer treatment devices that utilize synthetic biomarkers for early cancer detection. The company's approach involves a novel gene therapy technique known as Synthetic Biopsy, which prompts cancer cells to produce synthetic, non-human biomarkers. These biomarkers can be detected through various means, including blood, urine, or breath, allowing for timely tracking and treatment of cancer. By facilitating the early identification of cancer when it is still homogeneous, Earli aims to significantly enhance survival rates. Their technology not only aids in detection but is also applicable for therapeutic interventions, thereby personalizing treatment and improving patient outcomes.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.

Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.

Invoy is a company focused on providing personalized nutrition and wellness services through innovative monitoring medical devices. By utilizing science, data, and artificial intelligence, Invoy's technology captures real-time data on individual metabolism, allowing for tailored nutritional recommendations. The company aims to enhance individual health and weight loss goals by addressing the unique body chemistry of each person. With an emphasis on affordability, Invoy offers breath analyzers for medical applications, enabling users to effectively monitor their health and optimize their wellness journey.

SiPhox Health develops advanced diagnostic solutions for both home use and laboratory settings. The company offers an at-home test kit that evaluates 17 blood biomarkers, focusing on areas such as inflammation, hormonal health, metabolic fitness, and cardiovascular health. Their biosensing platform features a handheld device designed to work with disposable cartridges, integrating biochemistry and photonic chip technology. This innovative approach combines integrated photonics, electronics, and microfluidics to deliver sensitive readings of immunoassays and nucleic acids, facilitating point-of-need testing and enhancing the accessibility of diagnostic tools for users.

IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.

Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.

Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action. The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and how therapeutics work.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Karma Biotechnologies, Inc. is a Los Angeles-based startup focused on developing therapies for autoimmune diseases, allergies, and food sensitivities. Founded in 2019, the company offers Xavines, a precision immunotherapy platform designed to address the critical need for antigen-specific therapies that target only the rogue immune cells responsible for these conditions. Unlike traditional treatments that rely on general immune suppression, Karma Biotechnologies aims to create tolerogenic immunotherapies that promote antigen-specific immune tolerance in vivo. By leveraging its expertise in immunology and lipid nanoparticle engineering, the company seeks to provide innovative solutions that enhance the treatment landscape for autoimmune diseases and related disorders.

GEn1E Lifesciences Inc. is a biotechnology company based in Palo Alto, California, focused on developing innovative therapies for inflammatory and age-related diseases. Established in 2018, GEn1E employs a unique artificial intelligence platform to expedite the drug development process, targeting multiple mechanisms of action for protein therapeutics. Their portfolio includes MUC1-ED, an antibacterial therapy for pseudomonas infections, and a robust pipeline of over 21 novel immunomodulatory therapies aimed at rare diseases that currently lack effective treatments. The company’s AI-driven approach aims to significantly reduce the time and costs associated with drug development, with plans to advance additional therapies to investigational new drug (IND) status within the next year. GEn1E's team, comprised of experienced professionals in drug development and machine learning, is dedicated to creating life-saving treatments for patients in need, addressing the substantial unmet medical demands in the field.

Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.

Ceibo is an industrial biotechnology company dedicated to providing innovative solutions for the mining industry, particularly in the production of critical minerals essential for the clean energy transition. The company has developed proprietary technology for leaching copper sulfide, which enhances recovery from both primary and secondary sulfide ores rich in chalcopyrite. In addition to its leaching technology, Ceibo has implemented technologies aimed at dust suppression in mining operations. Currently, Ceibo operates within several large mining assets owned by prominent mining companies, focusing on optimizing processes, reducing costs, and promoting environmentally sustainable practices with a commitment to zero waste activity.

Overture Life, Inc. is a biotechnology company established in 2017 and headquartered in New York, New York. The company specializes in developing robotic technology and medical devices aimed at automating the in vitro fertilization (IVF) process. Overture Life's innovations include novel embryo testing methodologies and automated cryopreservation services, which help fertility clinics identify viable embryos prior to implantation. By streamlining the IVF process, Overture Life aims to make artificial insemination more accessible, reduce costs, optimize resource use, and improve success rates for practitioners and patients alike.

Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.

Probably Genetic is dedicated to providing solutions for individuals with rare genetic conditions that are often misdiagnosed as autism spectrum disorder. Recognizing that patients typically endure a lengthy wait of up to seven years for a proper diagnosis, the company aims to alleviate this prolonged uncertainty. They offer educational resources and DNA sequencing tests designed to help individuals and families understand whether there is a genetic basis for their symptoms. By facilitating access to crucial information and testing, Probably Genetic seeks to support those who may otherwise be overlooked by the healthcare system.

Neurotrack is a digital health company focused on transforming the diagnosis and management of Alzheimer's and other dementias. Founded in 2012 by Elli Kaplan and neuroscientist Dr. Stuart Zola, the company is headquartered in Redwood City, California. Neurotrack develops user-friendly, clinically validated cognitive assessments that can be administered in clinical settings or at home, allowing for early detection of cognitive impairment and ongoing monitoring of cognitive function. The company's solutions are designed to fit seamlessly into various workflows, enabling healthcare providers to efficiently screen patients for cognitive decline and take necessary next steps. Neurotrack has published 27 peer-reviewed papers, holds 11 patents for its proprietary technology, and is registered as an FDA Class II medical device.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.

Loop Genomics is a platform technology for long-read DNA sequencing. Loop Genomics technology transforms short-read DNA sequencers into high-throughput, long-read, single-molecule DNA sequencing machines. Loop Genomics long-read DNA sequencing technology provides phased sequencing solutions across a diverse repertoire of research and clinical applications. Sequencing of partial rRNA gene sequences results in reduced phylogenetic resolution. Full-length, high-throughput, phased sequencing that covers all 16S variable regions is becoming the gold standard for profiling the microbiome. Achieve the highest resolution microbial community profiling with long-read, next-generation sequencing of the microbiome. Characterizing polymorphisms in HLA genes inside and outside of the protein-coding regions is important for organ transplantation compatibility testing and for strengthening causality association studies. The length of homologous sequences between HLA alleles extends beyond the capabilities of short-read sequencing platforms, resulting in diploid ambiguities and a reliance on imputation. Sequence full-length HLA DNA and/or RNA with phased, high throughput, long-read sequencing that resolves allelic discrimination and diploid ambiguity. Viral genetic variability is a major determinant of viral drug resistance and viral vaccine efficacy. Accurately mapping viral genetic variability is a critical step in choosing the optimal course of therapy and developing efficacious vaccines. Key mutations are typically located throughout long stretches of viral genomes, making the retrieval of critical phased data challenging using short-read sequencing technology. Use phased, high-throughput DNA sequencing technology to map key mutations at the quasi-species level and generate a complete phased map of viral populations.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Viome, Inc. is a biotechnology company based in Bellevue, Washington, founded in 2016 by Naveen Jain. The company specializes in wellness monitoring kits that offer comprehensive health insights by analyzing various biological samples, including blood, urine, saliva, and stool. By examining the RNA from stool samples, Viome determines the composition of microbial communities in the digestive system, identifying different species and strains of bacteria, viruses, fungi, and other microorganisms. This analysis is integrated into a smartphone application that provides personalized recommendations for diet and lifestyle adjustments, aiding users in tracking their microbiome health, mitochondrial health, cellular health, and biological age. Viome's products are available through distributors and online, positioning the company as a leader in personalized health solutions.